Darcy Burbage on Assessing Risk for CIPN

May 23, 2016
Darcy Burbage, RN, MSN, AOCN, CBCN
Darcy Burbage, RN, MSN, AOCN, CBCN

Darcy has over 30 years of experience as an oncology nurse serving in a variety of roles. She is currently the Survivorship Nurse Navigator at the Helen F Graham Cancer Center & Research Institute. In addition to her clinical experience, she has held leadership positions in the local and national Oncology Nursing Society and has authored articles, book chapters, and has presented locally and nationally on numerous oncology topics. Darcy is passionate about mentoring new oncology nurses and helping patients maximize their quality of life.

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses risk factors that oncology nurses should be aware of when thinking about chemotherapy-induced peripheral neuropathy (CIPN).

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses risk factors that oncology nurses should be aware of when thinking about chemotherapy-induced peripheral neuropathy (CIPN).

Some patients may be at increased risk for CIPN, including those who have other comorbidities such as diabetes or fibromyalgia.

Regardless of comorbidities, Burbage says, the healthcare team must assess each patient before each chemotherapy treatment and ask about any numbness, tingling, trouble buttoning clothes, trouble walking, or general unsteadiness.

It is difficult to completely predict who will develop CIPN because some individuals do not have any risk factors and simply develop the side effect because of the medicine.